Xanomeline/trospium is a newly approved agent for the management of schizophrenia. Unlike traditional antipsychotics, which are D2 receptor antagonists, xanomeline is an M1/M4 muscarinic acetylcholine receptor agonist coformulated with trospium, a peripheral m... ...

请注册登录后继续浏览